- United Kingdom
- /
- Professional Services
- /
- AIM:TEK
Tekcapital Full Year 2024 Earnings: EPS: US$0.10 (vs US$0.091 loss in FY 2023)
Tekcapital (LON:TEK) Full Year 2024 Results
Key Financial Results
- Net income: US$19.2m (up from US$15.7m loss in FY 2023).
- EPS: US$0.10 (up from US$0.091 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tekcapital shares are up 16% from a week ago.
Risk Analysis
It is worth noting though that we have found 4 warning signs for Tekcapital (2 shouldn't be ignored!) that you need to take into consideration.
Valuation is complex, but we're here to simplify it.
Discover if Tekcapital might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:TEK
Tekcapital
Provides technology transfer services to universities and corporate clients in the United Kingdom and the United States.
Flawless balance sheet with slight risk.
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
SoFi Technologies: The Apex Aggregator and the Infrastructure of the Modern Financial System
CSL: The Dip Is the Opportunity
DHT Holdings, inc: Strait of Hormuz Risk Amidst US-Israel vs Iran Tensions Spikes VLCC Rates.
Recently Updated Narratives

Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Butler National (Buks) outperforms.

eToro: A High-Risk, Top-Tier Opportunity in the Future of Social Investing
Popular Narratives
Nu holdings will continue to disrupt the South American banking market
